Validation of anti-aging drugs by treating age-related diseases
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 1×
“[89, 90] Resveratrol was shown to prevent cancer, atherosclerosis, neurodegeneration and insulin-resistance (diabetes type II) [10, 91-100].”
BackgroundResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“[89, 90] Resveratrol was shown to prevent cancer, atherosclerosis, neurodegeneration and insulin-resistance (diabetes type II) [10, 91-100].”
BackgroundSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796 · cited 1×
“[89, 90] Resveratrol was shown to prevent cancer, atherosclerosis, neurodegeneration and insulin-resistance (diabetes type II) [10, 91-100].”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Remarkably, metformin decreases the incidence of breast cancer [7, 8].”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 3×
“Therefore, more selective activators of SIRT1 undergo clinical trials [3].”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677 · cited 1×
“Based on preclinical data, rapamycin has been considered in such pathologies as obesity [58], atherosclerosis [53-55], cardiac hypertrophy [59-64], aortic aneurysm [65], osteoporosis [66-68], organ fibrosis ( liver, renal, cardiac fibrosis) [64, 69, 70-75], neurodegeneration [76, 77], Alzheimer's disease [78, 79], Par…”
BackgroundKim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Influence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057 · cited 1×
“Genetic inhibition of the TOR pathway slows down aging in diverse organisms, including yeast, worms, flies and mice [29-33].”
Background
Cited by
Measuring population ageing: an analysis of the Global Burden of Disease Study 2017
Chang, A. Y., Skirbekk, V. F., Tyrovolas, S., Kassebaum, N. J., & Dieleman, J. L. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30019-2 · Cited by 820
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365
Anisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285
“It was suggested to use antidiabetic biguanides as a potential anti-aging treatment [3,10-14].”
BackgroundRapamycin Extends Maximal Lifespan in Cancer-Prone Mice
Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Antoch, M. P., & Blagosklonny, M. V. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091050 · Cited by 257
Self-citationAnti-senescence compounds: A potential nutraceutical approach to healthy aging
Gurău, F., Baldoni, S., Prattichizzo, F., Espinosa, E., Amenta, F., Procopio, A. D., Albertini, M. C., Bonafè, M., & Olivieri, F. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.001 · Cited by 179
Anisimov, V. N., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Tyndyk, M. L., Yurova, M. N., Zabezhinski, M. A., Anikin, I. V., Karkach, A. S., & Romanyukha, A. A. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10407 · Cited by 146
Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity
Deng, L., Cai, Y., Zhang, W., Yang, W., Gao, B., & Liu, H. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00331 · Cited by 71
Rapamycin-Induced Glucose Intolerance: Hunger or Starvation Diabetes
Blagosklonny, M. V. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18595 · Cited by 59
Self-citationHalicka, H. D., Zhao, H., Li, J., Traganos, F., Zhang, S., Lee, M., & Darzynkiewicz, Z. (2011) · Aging · doi:10.18632/aging.100397 · Cited by 53
“The persistent replication stress combined with activation of mTOR pathways is considered to be the main mechanism contributing to aging and senescence [22-27,69,70].”
BackgroundMakarev, E., Cantor, C., Zhavoronkov, A., Buzdin, A., Aliper, A., & Csoka, A. B. (2014) · Aging · doi:10.18632/aging.100711 · Cited by 50
“The intimate interplay of tissue-specific signaling pathway activation in AMD with age may shed new light into other agerelated diseases and eventually aging itself [36, 37].”
BackgroundBioenergetics of the aging heart and skeletal muscles: Modern concepts and controversies
Tepp, K., Timohhina, N., Puurand, M., Klepinin, A., Chekulayev, V., Shevchuk, I., & Kaambre, T. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.001 · Cited by 21
Metadata
- Authors
- Blagosklonny, M. V.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2009-03-28
- Volume
- 1
- Issue
- 3
- Pages
- 281-288
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2102680614
- Cited by
- 140
- References
- 21
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.